NCT05481775 2022-11-21Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung CancerSun Yat-sen UniversityPhase 2 Withdrawn